EMA Authorised: Ruconest (recombinant human C1-inhibitor) — Pharming Group N.V.

View source ↗

Summary

The EMA authorised Ruconest (recombinant human C1-inhibitor) for hereditary angioedema, with marketing authorization granted to Pharming Group N.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Ruconest (conestat alfa)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: Pharming Group N.V.. Decision date: 29/08/2024